Atossa Therapeutics (ATOS) Cash from Financing Activities (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Cash from Financing Activities of $3.4 million for Q4 2024, up 3269.0% quarter-over-quarter from $100000.0 in Q2 2024.
Atossa Therapeutics (ATOS) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Cash from Financing Activities for 12 consecutive years, with $3.4 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Financing Activities changed N/A year-over-year to $3.4 million; the TTM figure through Sep 2025 stood at $3.4 million (up 1008.22% YoY), while the FY2024 annual figure was $3.7 million, up 349.02% from the prior year.
- Cash from Financing Activities rose to $3.4 million in Q4 2024 per ATOS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $102.4 million in Q1 2021 and bottomed at -$1.5 million in Q3 2023.
- Historically, Cash from Financing Activities has averaged $15.4 million across 4 years, with a median of $2.0 million in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 84.3% in 2021 and fell as far as 100.0% in 2021.
- Atossa Therapeutics' Cash from Financing Activities stood at $33.9 million in 2020, then tumbled by 100.0% to $1000.0 in 2021, then slumped by 147600.0% to -$1.5 million in 2023, then soared by 328.41% to $3.4 million in 2024.
- Business Quant data shows ATOS's Cash from Financing Activities at $3.4 million in Q4 2024, $100000.0 in Q2 2024, and $204000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Jun 30, 2026 | 4.02 Mn |
| Dec 31, 2024 | 3.37 Mn |
| Dec 31, 2024 | 3.37 Mn |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 679,000.00 |
| Sep 30, 2021 | 679,000.00 |
| Jun 30, 2021 | 10.20 Mn |
| Jun 30, 2021 | 10.20 Mn |
| Mar 31, 2021 | 102.43 Mn |
| Mar 31, 2021 | 102.43 Mn |
| Dec 31, 2020 | 33.88 Mn |
| Dec 31, 2020 | 33.88 Mn |